Compare General Mills, Inc. (GIS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Merck & Co., Inc. — how do they compare? General Mills, Inc. trades at $32.1 (market cap $17.43B), while Merck & Co., Inc. trades at $145.72 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 20.2× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (7.49%). Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Merck & Co., Inc. for 98 Days on average.
| GIS | MRK | |
|---|---|---|
Market Cap | $17.43B | $351.28B |
Volume | 16,554,362 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $156.43 |
52-Week Low | $31.67 | $82.49 |
Typical Hold Time | 106 Days | 98 Days |
Enterprise Value | $30.61B | $398.04B |
Dividend Yield | 7.49% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.09, up 1.01% with mixed technical signals showing bearish moving averages but neutral oscillators. The company faces fundamental challenges with a negative net income margin of -4.89% and ROE of -10.55% for 2026, though it maintains strong operating cash flow of $2.92B in 2025. Recent leadership transition to Dana McNabb as CEO and a $3B cost-saving initiative aim to stabilize performance amid declining revenues.
The stock presents a value opportunity with a low P/E of 9.23 and a 7.6% upside to the $36 consensus target, supported by a reliable dividend. However, risks include persistent margin pressures, high debt levels at 45% of assets, and competitive headwinds in the packaged foods sector. Analyst sentiment is cautious with 61% hold ratings, reflecting uncertainty around the turnaround strategy's execution.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
